A 90-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s disease (AD) to investigate the safety, efficacy, and antibody response to seven injections of CAD106 in combination with an adjuvant.
This is a 90-week placebo-controlled study evaluating IM injections of a vaccine for patients with mild Alzheimer’s. If enrolled in the study, the likelihood of receiving active drug is 7 out of 8.
Major Inclusion/ Exclusion Criteria:
- Below 85 years of age
- MMSE 20-26 inclusive
- Auto-immune disease is excluded
- More than 2 cerebral micro-hemorrhages on MRI will exclude the patient